(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Invigorating Spots To Go Kayaking All over The Planet - 2The Solution to Individual budget: Dominating Cash The board
- 3The Most Notable Design Brands of the 21st Hundred years
- 4Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- 5Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- Which Film Has the Incomparable Melodic Score?
- 21 Things You Ought to Never Tell Your Childless Companion
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- The Best 15 Applications for Efficiency and Association
- The Best Internet based Retailers for Style and Frill
- Manual for Tracking down Special Store Lodgings
- Distributed storage Answers for Information Reinforcement
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- Fundamental Home Items Each Animal person Needs
